| Alopecia group (n = 138, 8.2%) | Non-alopecia group (n = 1550, 91.8%) | P value |
---|---|---|---|
Female ratio | 67.4% (93/138) | 59.7% (924/1547) | 0.0845 |
Age at MG onset, y | 45.5 ± 17.2 | 48.3 ± 18.6 | 0.1078 |
Disease duration of MG, y | 13.0 ± 10.5 | 12.0 ± 11.2 | 0.0565 |
Worst quantitative MG score | 13.8 ± 7.4 | 12.6 ± 13.8 | 0.1061 |
History of bulbar palsy | 59.4% (82/138) | 50.3% (770/1531) | 0.0412 |
History of crisis | 8.0% (11/138) | 8.4% (129/1529) | 1.0000 |
MM or better status, current status | 60.9% (84/138) | 57.2% (886/1550) | 0.4197 |
Refractory MG | 23.5% (32/136) | 20.9% (312/1494) | 0.5099 |
MG subtype | Â | Â | 0.0428 |
 Ocular MG | 15.9% (22/138) | 22.1% (340/1540) | 0.1050 |
 EOMG | 23.9% (33/138) | 21.0% (323/1540) | 0.4466 |
 LOMG | 16.7% (23/138) | 20.8% (320/1540) | 0.2722 |
 TAMG | 32.6% (45/138) | 21.8% (337/1540) | 0.0057 |
 MuSKMG | 1.4% (2/138) | 3.1% (47/1540) | 0.4273 |
 SNMG | 9.4% (13/138) | 11.2% (173/1540) | 0.5742 |
Alopecia | Â | Â | Â |
 Onset after MG onset | 36.8% (49/133) | - | - |
 Response to MG treatments | 44.3% (47/106) | - | - |
 Onset after thymectomy | 35.3% (24/68) | - | - |